IP Library Granted Patent US 9,340,524
Granted Patent B2
US 9,340,524 · App. 14/151,106 · Granted May 17, 2016

Androgen receptor modulator and uses thereof

Inventors: Isan Chen (San Diego, CA); Jeffrey H Hager (San Diego, CA); Edna Chow Maneval (San Diego, CA); Mark R Herbert (San Diego, CA); Nicholas D Smith (San Diego, CA)
Assignee: Aragon Pharmaceuticals, Inc.
C07D401/04A61K9/4825A61K31/337A61K31/4025A61K31/436A61K31/4439A61K31/5377A61K31/58A61K38/09A61K39/39558A61K45/06A61K51/025A61K51/1096A61K9/0019A61K9/0024A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,340,524
App. No.
14/151,106
Granted
May 17, 2016
Kind
B2
Abstract

Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.

Claims (4)

1. A pharmaceutical composition comprising a nonaqueous, lipid-based solution of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, in a softgel capsule, wherein the composition comprises the compound of Formula (I), or a pharmaceutically acceptable salt thereof, vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate NF (Vitamin E TPGS), polyethylene glycol 400 NF/EP (PEG 400), glycerol monocaprylocaprate EP and caprylocaproyl macroglycerides EP/NF

2. The pharmaceutical composition of claim 1 , wherein the nonaqueous, lipid-based solution the compound of Formula (I), or a pharmaceutically acceptable salt thereof, comprises about 3 wt % of the compound of Formula (I), or a pharmaceutically acceptable salt thereof,

3. The pharmaceutical composition of 1 , wherein the softgel capsule shell comprises gelatin NF/EP, a 50:50 sorbitol/glycerin blend USP/EP, and purified water USP/EP.

4. The pharmaceutical composition of claim 1 , wherein a single unit dosage comprises about 30 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof,

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2014
From: CHEN, ISAN; HAGER, JEFFREY H.; MANEVAL, EDNA CHOW; HERBERT, MARK R.; SMITH, NICHOLAS D.
To: ARAGON PHARMACEUTICALS, INC.
Reel/Frame 032324/0255 →
Continuity (2)
Provisional Application 61752842 · Jan 15, 2013
Related Publication 20140199236A1 · Jul 17, 2014